These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 33895125)

  • 21. Parathyroid hormone variability parameters for identifying high turnover osteodystrophy disease in hemodialysis patients: an observational retrospective cohort study.
    De Paola L; Coppolino G; Bolignano D; Buemi M; Lombardi L
    Ther Apher Dial; 2010 Dec; 14(6):566-71. PubMed ID: 21118364
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evolution of the parathyroid hormone (PTH) assay--importance of circulating PTH immunoheterogeneity and of its regulation.
    Gao P; D'Amour P
    Clin Lab; 2005; 51(1-2):21-9. PubMed ID: 15719701
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of Second- and Third-Generation Parathyroid Hormone Test Results in Patients with Chronic Kidney Disease.
    Wójtowicz M; Piechota W; Wańkowicz Z; Smoszna J; Niemczyk S
    Med Sci Monit; 2020 Dec; 26():e928301. PubMed ID: 33361742
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Parathyroid suppression therapy normalizes chronic kidney disease-induced elevations in cortical bone vascular perfusion: a pilot study.
    Aref MW; Swallow EA; Metzger CE; Chen N; Moe SM; Allen MR
    Osteoporos Int; 2019 Aug; 30(8):1693-1698. PubMed ID: 31069439
    [TBL] [Abstract][Full Text] [Related]  

  • 25. GFR-Specific versus GFR-Agnostic Cutoffs for Parathyroid Hormone and Fibroblast Growth Factor-23 in Advanced Chronic Kidney Disease.
    Canney M; Djurdjev O; Tang M; Zierold C; Blocki F; Wolf M; Levin A
    Am J Nephrol; 2019; 50(2):105-114. PubMed ID: 31238301
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The case for routine parathyroid hormone monitoring.
    Sprague SM; Moe SM
    Clin J Am Soc Nephrol; 2013 Feb; 8(2):313-8. PubMed ID: 23037984
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Parathyroid Hormone Measurement in Chronic Kidney Disease: From Basics to Clinical Implications.
    Kritmetapak K; Pongchaiyakul C
    Int J Nephrol; 2019; 2019():5496710. PubMed ID: 31637056
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of Nonoxidized Parathyroid Hormone with Cardiovascular and Kidney Disease Outcomes in Chronic Kidney Disease.
    Seiler-Mussler S; Limbach AS; Emrich IE; Pickering JW; Roth HJ; Fliser D; Heine GH
    Clin J Am Soc Nephrol; 2018 Apr; 13(4):569-576. PubMed ID: 29507005
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The relationship between intact PTH and biointact PTH (1-84) with bone and mineral metabolism in pre-dialysis chronic kidney disease (CKD).
    O'Flaherty D; Sankaralingam A; Scully P; Manghat P; Goldsmith D; Hampson G
    Clin Biochem; 2013 Oct; 46(15):1405-9. PubMed ID: 23830844
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PTH determination in hemodialyzed patients-A laboratory perspective.
    Cavalier E; Souberbielle JC; Delanaye P
    Semin Dial; 2019 Nov; 32(6):490-492. PubMed ID: 31631422
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The evolution of assays for parathyroid hormone.
    Goodman WG
    Semin Dial; 2005; 18(4):296-301. PubMed ID: 16076352
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of four different PTH methods on the classification of chronic kidney disease patients according to the new KDIGO guideline.
    Ten BE; Van Veen MC; Vervloet MG; Fischer JC; Koopman MG; Van Dam B
    Clin Lab; 2012; 58(7-8):719-24. PubMed ID: 22997972
    [TBL] [Abstract][Full Text] [Related]  

  • 33. KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).
    Isakova T; Nickolas TL; Denburg M; Yarlagadda S; Weiner DE; Gutiérrez OM; Bansal V; Rosas SE; Nigwekar S; Yee J; Kramer H
    Am J Kidney Dis; 2017 Dec; 70(6):737-751. PubMed ID: 28941764
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Practical considerations in PTH testing.
    Souberbielle JC; Friedlander G; Cormier C
    Clin Chim Acta; 2006 Apr; 366(1-2):81-9. PubMed ID: 16310759
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Similar predictive value of bone turnover using first- and second-generation immunometric PTH assays in pediatric patients treated with peritoneal dialysis.
    Salusky IB; Goodman WG; Kuizon BD; Lavigne JR; Zahranik RJ; Gales B; Wang HJ; Elashoff RM; Jüppner H
    Kidney Int; 2003 May; 63(5):1801-8. PubMed ID: 12675856
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum bone markers in ROD patients across the spectrum of decreases in GFR: Activin A increases before all other markers
.
    Lima F; Mawad H; El-Husseini AA; Davenport DL; Malluche HH
    Clin Nephrol; 2019 Apr; 91(4):222-230. PubMed ID: 30862350
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The assay of the hypocalcemic PTH fragment inhibitor with PTH provides a more accurate assessment of renal osteodystrophy compared to the intact PTH assay.
    Cantor T; Sci B
    Nefrologia; 2003; 23 Suppl 2():69-72. PubMed ID: 12778858
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FGF23 and the PTH response to paricalcitol in chronic kidney disease.
    D'Arrigo G; Pizzini P; Cutrupi S; Tripepi R; Tripepi G; Mallamaci F; Zoccali C
    Eur J Clin Invest; 2020 Feb; 50(2):e13196. PubMed ID: 31863599
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Parathyroid hormone (PTH), PTH-derived peptides, and new PTH assays in renal osteodystrophy.
    Goodman WG; Jüppner H; Salusky IB; Sherrard DJ
    Kidney Int; 2003 Jan; 63(1):1-11. PubMed ID: 12472763
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.